Brought to you by 
BioMerieux goes public
09 Jul 2004
Executive Summary
Prompted by investment firm Wendel Investissment's desire to sell its 34.5% stake, bioMerieux SA has gone public in a five times oversubscribed offering. It listed only Wendel's stock (29.5%--11.5mm shares including the overallotment) on the Premier Marche of Euronext Paris at a price of €30 ($36.86) apiece, near the high end of its original range of €26.90-31.25. Additionally, in a private placement capped at €22mm, BioMerieux offered its employees about 1mm shares priced at €24 apiece, a 20% discount to the IPO closing price.
Deal Industry
- In Vitro Diagnostics
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Saliva-based Testing
- Urine-based Testing
Deal Status
- Final
Deal Type
-
Financing
- IPO
- Other
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioMerieux goes public
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice